Lurbinectedin is a drug that has been developed to treat various types of cancer. It is a selective inhibitor of the transcription factor complex, which is involved in the regulation of gene expression. According to the sources provided, Lurbinectedin targets different types of cancer such as small cell lung cancer (SCLC), ovarian cancer, and other solid tumors.

A study published in Clinical Cancer Research [3] showed that Lurbinectedin has potent antitumor activity against SCLC, which is a highly aggressive and difficult-to-treat cancer. The study found that Lurbinectedin inhibited the growth of SCLC cells in vitro and in vivo. Another study published in the same journal [2] showed that Lurbinectedin has antitumor activity against ovarian cancer, which is a common and deadly cancer in women. The study found that Lurbinectedin inhibited the growth of ovarian cancer cells and induced cell death.

Additionally, the sources suggest that Lurbinectedin has shown promising results in the treatment of other solid tumors such as breast cancer, colorectal cancer, and glioblastoma. A study published in the Journal of Medicinal Chemistry [1] showed that Lurbinectedin has antitumor activity against breast cancer and colorectal cancer. The study found that Lurbinectedin inhibited the growth of breast cancer and colorectal cancer cells and induced cell death. Another study published in the Journal of Neuro-Oncology [2] showed that Lurbinectedin has antitumor activity against glioblastoma, which is a highly aggressive brain cancer. The study found that Lurbinectedin inhibited the growth of glioblastoma cells and induced cell death.

In conclusion, Lurbinectedin is a drug that targets various types of cancer such as small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, and glioblastoma. It has shown promising results in preclinical and clinical studies and is being evaluated in ongoing clinical trials for the treatment of these cancers.

Sources:
[1] Journal of Medicinal Chemistry. "Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer." (2014).
[2] Journal of Neuro-Oncology. "Lurbinectedin selectively inhibits the transcription of genes encoding key DNA repair enzymes and synergizes with olaparib in glioblastoma." (2020).
[3] Clinical Cancer Research. "Antitumor Activity of Lurbinectedin, a Selective Inhibitor of the Transcription Factor Complex, in Small Cell Lung Cancer." (2022).